risperidone has been researched along with Delirium in 84 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Delirium: A disorder characterized by CONFUSION; inattentiveness; disorientation; ILLUSIONS; HALLUCINATIONS; agitation; and in some instances autonomic nervous system overactivity. It may result from toxic/metabolic conditions or structural brain lesions. (From Adams et al., Principles of Neurology, 6th ed, pp411-2)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of delirium often includes haloperidol." | 9.34 | Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020) |
| "To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care." | 9.24 | Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. ( Agar, MR; Caplan, GA; Currow, DC; Devilee, L; Draper, B; Eckermann, S; Fazekas, B; Hardy, J; Hill, M; Lawlor, PG; Le, B; McCaffrey, N; Quinn, S; Rowett, D; Sanderson, C, 2017) |
| "Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission." | 9.16 | Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012) |
| "7%) patients in the risperidone group experienced delirium versus 17 (34%) in the placebo group (P = 0." | 9.16 | Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: a randomized trial. ( Hakim, SM; Naoum, DO; Othman, AI, 2012) |
| " haloperidol in patients of delirium admitted to medical and surgical wards." | 9.15 | Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. ( Chakrabarti, S; Grover, S; Kumar, V, 2011) |
| "This randomised, double-blinded, placebo-controlled study was primarily aimed to evaluate the potential of risperidone to prevent postoperative delirium following cardiac surgery with cardiopulmonary bypass and the secondary objective was to explore clinical factors associated with postoperative delirium." | 9.12 | Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. ( Prakanrattana, U; Prapaitrakool, S, 2007) |
| "The present study aimed to examine the relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium." | 9.11 | Relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium. ( Ito, K; Koyama, T; Kusumi, I; Sasaki, Y; Toda, H, 2005) |
| "Low-dose risperidone can improve cognitive and behavioral symptoms of delirium in medically ill patients." | 9.11 | Risperidone in the treatment of delirium: results from a prospective open-label trial. ( Jimerson, NA; Johnson, WD; Kennedy, RE; Mittal, D; Nasrallah, HA; Neely, EP; Torres, RA, 2004) |
| "The aim of this study was to evaluate the efficacy and safety of risperidone in the treatment of patients with delirium." | 9.11 | Risperidone in the treatment of patients with delirium. ( Baeza, I; de Pablo, J; Martínez, G; Parellada, E, 2004) |
| "The clinical benefit of perospirone for treatment of delirium in patients with advanced cancer is not sufficiently clear." | 8.12 | Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings. ( Inoue, S; Maeda, I; Ogawa, A; Terada, S; Yamada, N; Yoshiuchi, K, 2022) |
| "The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium." | 7.81 | Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. ( Boettger, S; Breitbart, W; Jenewein, J, 2015) |
| "This study was a 6-day, prospective, comparative clinical observational study of haloperidol versus atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in patients with delirium at a tertiary level hospital." | 7.79 | Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. ( Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013) |
| "The aim of this study was to determine the risk of adverse events for risperidone and haloperidol in delirium patients." | 7.74 | Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. ( Hoshino, S; Miyaji, S; Miyaoka, H; Sakai, Y; Yamamoto, H; Yamamoto, K, 2007) |
| "Drug-induced delirium can occur with several drugs, including diphenhydramine." | 7.72 | Acute delirium associated with combined diphenhydramine and linezolid use. ( Serio, RN, 2004) |
| "Oral risperidone was given once a day (0." | 5.43 | Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer. ( Inoue, K; Matsuda, Y; Nakao, Y; Takemura, M; Tsuruta, R; Yabe, M, 2016) |
| "A 59-year-old man with nonalcoholic steatohepatitis cirrhosis underwent an orthotopic liver transplant and experienced a complicated postoperative course, including a prolonged delirium." | 5.43 | Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine. ( Brown, GD; Muzyk, AJ; Preud'homme, XA, 2016) |
| "Long-acting injectable (LAI) formulations of antipsychotics are valuable treatment alternatives for patients with psychotic disorders, and understanding their safe use is critical." | 5.37 | Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases. ( Alphs, L; Gopal, S; Karcher, K; Kent, J; Kushner, S; Nuamah, I; Singh, J; Sliwa, JK, 2011) |
| "Treatment of delirium often includes haloperidol." | 5.34 | Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020) |
| "Risperidone may prove to be an effective alternative to haloperidol in delirious patients, especially the elderly and the severely medically ill, who are more prone to adverse effects." | 5.30 | Use of risperidone in delirium: case reports. ( Masand, PS; Sipahimalani, A, 1997) |
| "To determine efficacy of risperidone or haloperidol relative to placebo in relieving target symptoms of delirium associated with distress among patients receiving palliative care." | 5.24 | Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial. ( Agar, MR; Caplan, GA; Currow, DC; Devilee, L; Draper, B; Eckermann, S; Fazekas, B; Hardy, J; Hill, M; Lawlor, PG; Le, B; McCaffrey, N; Quinn, S; Rowett, D; Sanderson, C, 2017) |
| "Risperidone with routine clinical management was effective for the treatment of delirium: 48% of the patients responded and 38% achieved remission." | 5.16 | Treatment of delirium with risperidone in cancer patients. ( Kato, M; Kishi, Y; Okuyama, T; Thurber, S, 2012) |
| "7%) patients in the risperidone group experienced delirium versus 17 (34%) in the placebo group (P = 0." | 5.16 | Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: a randomized trial. ( Hakim, SM; Naoum, DO; Othman, AI, 2012) |
| " haloperidol in patients of delirium admitted to medical and surgical wards." | 5.15 | Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. ( Chakrabarti, S; Grover, S; Kumar, V, 2011) |
| "This randomised, double-blinded, placebo-controlled study was primarily aimed to evaluate the potential of risperidone to prevent postoperative delirium following cardiac surgery with cardiopulmonary bypass and the secondary objective was to explore clinical factors associated with postoperative delirium." | 5.12 | Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. ( Prakanrattana, U; Prapaitrakool, S, 2007) |
| "The aim of this study was to evaluate the efficacy and safety of risperidone in the treatment of patients with delirium." | 5.11 | Risperidone in the treatment of patients with delirium. ( Baeza, I; de Pablo, J; Martínez, G; Parellada, E, 2004) |
| "Low-dose risperidone can improve cognitive and behavioral symptoms of delirium in medically ill patients." | 5.11 | Risperidone in the treatment of delirium: results from a prospective open-label trial. ( Jimerson, NA; Johnson, WD; Kennedy, RE; Mittal, D; Nasrallah, HA; Neely, EP; Torres, RA, 2004) |
| "The present study aimed to examine the relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium." | 5.11 | Relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium. ( Ito, K; Koyama, T; Kusumi, I; Sasaki, Y; Toda, H, 2005) |
| "Combination lithium, a mood stabilizer, and risperidone, an atypical antipsychotic drug, is widely used for treatment of psychotic disorders." | 4.93 | Neurotoxicity and nephrotoxicity caused by combined use of lithium and risperidone: a case report and literature review. ( Hsu, CW; Lee, CY; Lee, Y; Lin, PY, 2016) |
| "The use of antipsychotics for surgical ICU patients and dexmedetomidine for mechanically ventilated patients as a preventive strategy may reduce the prevalence of delirium in the ICU." | 4.91 | Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review. ( Bozza, FA; do Brasil, PE; Ely, EW; Salluh, JI; Serafim, RB; Soares, M; Tura, BR, 2015) |
| "To compare the efficacy and incidence of adverse effects of haloperidol with risperidone, olanzapine, and quetiapine in the treatment of delirium." | 4.84 | Antipsychotics for delirium. ( Britton, AM; Lonergan, E; Luxenberg, J; Wyller, T, 2007) |
| "Risperidone, the most thoroughly studied atypical antipsychotic, was found to be approximately 80% to 85% effective in treating the behavioral disturbances of delirium at a dosage of 0." | 4.84 | Atypical antipsychotics for the treatment of delirious elders. ( Kaiser, RM; Ozbolt, LB; Paniagua, MA, 2008) |
| "Overall 13 studies examined the use of risperidone, olanzapine, and quetiapine, two cases were reported about ziprasidone, and no publication was found using aripiprazole in the treatment of delirium." | 4.82 | Atypical antipsychotics in the management of delirium: a review of the empirical literature. ( Boettger, S; Breitbart, W, 2005) |
| "The clinical benefit of perospirone for treatment of delirium in patients with advanced cancer is not sufficiently clear." | 4.12 | Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings. ( Inoue, S; Maeda, I; Ogawa, A; Terada, S; Yamada, N; Yoshiuchi, K, 2022) |
| "5%), more than 68% recommended the use of risperidone or quetiapine administered orally for hyperactive delirium, except in patients with comorbid diabetes and renal dysfunction." | 3.83 | Expert opinions on the first-line pharmacological treatment for delirium in Japan: a conjoint analysis. ( Hatta, K; Kishi, Y; Okumura, Y; Takeuchi, T; Wada, K, 2016) |
| "To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS)." | 3.83 | Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study. ( Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M, 2016) |
| "The aim of this study was to compare the efficacy and side-effect profile of the typical antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and aripiprazole in the management of delirium." | 3.81 | Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects. ( Boettger, S; Breitbart, W; Jenewein, J, 2015) |
| "This study was a 6-day, prospective, comparative clinical observational study of haloperidol versus atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in patients with delirium at a tertiary level hospital." | 3.79 | Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium. ( Choi, SH; Choi, WJ; Kim, JJ; Park, JY; Park, KM; Seok, JH; Yoon, HJ, 2013) |
| " Patients suffering from delirium were mostly treated with an antipsychotic: 147 (77%) were treated either with risperidone (73 patients) or classical antipsychotics (74 patients)." | 3.76 | Treating delirium in a general hospital: a descriptive study of prescribing patterns and outcomes. ( Barak, Y; Briskman, I; Dubinski, R, 2010) |
| "The aim of this study was to determine the risk of adverse events for risperidone and haloperidol in delirium patients." | 3.74 | Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. ( Hoshino, S; Miyaji, S; Miyaoka, H; Sakai, Y; Yamamoto, H; Yamamoto, K, 2007) |
| " We present a case of post-traumatic delirium with delusions treated with Risperidone and discuss the use of AAP's in this situation." | 3.72 | Use of atypical anti-psychotics in the management of post-traumatic confusional states in traumatic brain injury. ( Temple, MJ, 2003) |
| "Drug-induced delirium can occur with several drugs, including diphenhydramine." | 3.72 | Acute delirium associated with combined diphenhydramine and linezolid use. ( Serio, RN, 2004) |
| "Delirium is likely present in the neonatal intensive care unit and has been largely unrecognized." | 2.82 | Delirium in the Neonate. ( Adams, SJ; Sprecher, A, 2022) |
| "Patients with delirium are frequently treated with antipsychotic medications that are well known to induce akathisia as a side effect." | 2.53 | Antipsychotic-induced akathisia in delirium: A systematic review. ( Alici, Y; Forcen, FE; Matsoukas, K, 2016) |
| "Delirium is a complex but common disorder in palliative care with a prevalence between 13 and 88 % but a particular frequency at the end of life (terminal delirium)." | 2.52 | Management of delirium in palliative care: a review. ( Berardi, MA; Caraceni, A; Caruso, R; Grassi, L; Mitchell, AJ; Nanni, MG; Riba, M, 2015) |
| "Delirium is a serious and common problem in severely medically ill patients of all ages." | 2.50 | The pharmacologic management of delirium in children and adolescents. ( Hanft, A; Turkel, SB, 2014) |
| "Delirium is a common problem in older patients admitted to the hospital." | 2.44 | [Delirium--management in the hospital: diagnosis and treatment]. ( Rahn, A, 2008) |
| " Risperidone has weight-based dosing and a liquid dosage form available, making it a good option for use in the NICU." | 1.62 | Delirium in the NICU: Risk or Reality? ( Liviskie, C; McPherson, C, 2021) |
| "Infant delirium is an under-recognized clinical entity in neonatal intensive care, and earlier identification and treatment could minimize morbidities associated with this condition." | 1.46 | A case of infant delirium in the neonatal intensive care unit. ( Bidegain, M; Cotten, CM; Edwards, LE; Hornik, CD; Hutchison, LB; Smith, PB, 2017) |
| "Oral risperidone was given once a day (0." | 1.43 | Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer. ( Inoue, K; Matsuda, Y; Nakao, Y; Takemura, M; Tsuruta, R; Yabe, M, 2016) |
| "A 59-year-old man with nonalcoholic steatohepatitis cirrhosis underwent an orthotopic liver transplant and experienced a complicated postoperative course, including a prolonged delirium." | 1.43 | Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine. ( Brown, GD; Muzyk, AJ; Preud'homme, XA, 2016) |
| "Long-acting injectable (LAI) formulations of antipsychotics are valuable treatment alternatives for patients with psychotic disorders, and understanding their safe use is critical." | 1.37 | Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases. ( Alphs, L; Gopal, S; Karcher, K; Kent, J; Kushner, S; Nuamah, I; Singh, J; Sliwa, JK, 2011) |
| "Delirium is a transient global disorder of cognition." | 1.33 | Elderly patient with delirium after myocardial infarction. ( Ariogul, S; Cankurtaran, ES; Cankurtaran, M; Halil, M; Ozkayar, N; Shorbagi, A; Ulger, Z; Yavuz, BB, 2006) |
| "Risperidone may prove to be an effective alternative to haloperidol in delirious patients, especially the elderly and the severely medically ill, who are more prone to adverse effects." | 1.30 | Use of risperidone in delirium: case reports. ( Masand, PS; Sipahimalani, A, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (8.33) | 18.2507 |
| 2000's | 22 (26.19) | 29.6817 |
| 2010's | 46 (54.76) | 24.3611 |
| 2020's | 9 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, SJ | 1 |
| Sprecher, A | 1 |
| Inoue, S | 1 |
| Maeda, I | 2 |
| Ogawa, A | 1 |
| Yoshiuchi, K | 1 |
| Terada, S | 1 |
| Yamada, N | 1 |
| Sugawara, H | 1 |
| Koyama, A | 1 |
| Maruyama, T | 1 |
| Koda, Y | 1 |
| Fukunaga, H | 1 |
| Ishikawa, T | 1 |
| Takebayashi, M | 1 |
| Okamoto, K | 1 |
| Fukui, T | 1 |
| Hashimoto, M | 1 |
| Tsai, DH | 1 |
| Chang, WH | 1 |
| Lin, HW | 1 |
| Lin, SJ | 1 |
| Shao, SC | 1 |
| Lai, EC | 1 |
| Raphael, L | 1 |
| Edna, E | 1 |
| Irina, K | 1 |
| Oded, H | 1 |
| Marcantonio, ER | 1 |
| van der Vorst, MJDL | 1 |
| Neefjes, ECW | 1 |
| Boddaert, MSA | 1 |
| Verdegaal, BATT | 1 |
| Beeker, A | 1 |
| Teunissen, SCC | 1 |
| Beekman, ATF | 1 |
| Wilschut, JA | 1 |
| Berkhof, J | 1 |
| Zuurmond, WWA | 1 |
| Verheul, HMW | 1 |
| Kim, MS | 1 |
| Rhim, HC | 1 |
| Park, A | 1 |
| Kim, H | 1 |
| Han, KM | 1 |
| Patkar, AA | 1 |
| Pae, CU | 1 |
| Han, C | 2 |
| Joshi, S | 1 |
| Krstacic, J | 1 |
| Mallangada, N | 1 |
| Coriolan, S | 1 |
| Karampahtsis, C | 1 |
| Liviskie, C | 1 |
| McPherson, C | 1 |
| Shrikant Kulkarni, N | 1 |
| Lee, J | 1 |
| Holbrook, A | 1 |
| Hui, D | 1 |
| Valentine, A | 1 |
| Bruera, E | 1 |
| Bogman, ACCF | 1 |
| Schieveld, JNM | 1 |
| Elsayem, AF | 1 |
| Fisch, MJ | 1 |
| Morgan, AA | 1 |
| Sinclair, CT | 1 |
| Agar, MR | 2 |
| Draper, B | 2 |
| Caplan, GA | 2 |
| Thom, RP | 1 |
| Mock, CK | 1 |
| Teslyar, P | 1 |
| Burry, L | 1 |
| Mehta, S | 1 |
| Perreault, MM | 1 |
| Luxenberg, JS | 1 |
| Siddiqi, N | 1 |
| Hutton, B | 1 |
| Fergusson, DA | 1 |
| Bell, C | 1 |
| Rose, L | 1 |
| Uenishi, S | 1 |
| Takahashi, S | 1 |
| Nakayama, Y | 1 |
| Hiwatani, Y | 1 |
| Nakane, S | 1 |
| Tsuji, T | 1 |
| Ukai, S | 1 |
| Matsuda, Y | 2 |
| Nakao, Y | 1 |
| Yabe, M | 1 |
| Tsuruta, R | 1 |
| Takemura, M | 1 |
| Inoue, K | 1 |
| Tsuda, A | 1 |
| Nishimura, K | 1 |
| Naganawa, E | 1 |
| Otsubo, T | 1 |
| Ishigooka, J | 1 |
| Meagher, DJ | 1 |
| McLoughlin, L | 1 |
| Leonard, M | 1 |
| Hannon, N | 1 |
| Dunne, C | 1 |
| O'Regan, N | 1 |
| Turkel, SB | 3 |
| Jacobson, JR | 1 |
| Tavaré, CJ | 2 |
| Wang, HR | 1 |
| Woo, YS | 1 |
| Bahk, WM | 1 |
| Yoon, HJ | 1 |
| Park, KM | 1 |
| Choi, WJ | 1 |
| Choi, SH | 1 |
| Park, JY | 1 |
| Kim, JJ | 1 |
| Seok, JH | 1 |
| Lu, YY | 1 |
| Hsueh, JH | 1 |
| Wei, IH | 1 |
| Huang, CC | 1 |
| Farrell, H | 1 |
| Eastman, P | 1 |
| Hanft, A | 1 |
| Boettger, S | 3 |
| Jenewein, J | 2 |
| Breitbart, W | 2 |
| Andersen, CU | 2 |
| Høimark, L | 2 |
| Dabrowski, K | 2 |
| Hansen, KB | 2 |
| Sædder, E | 2 |
| Tanimukai, H | 1 |
| Tsujimoto, H | 1 |
| Tokoro, A | 1 |
| Kanemura, S | 1 |
| Watanabe, M | 1 |
| Tsujio, I | 1 |
| Takei, K | 1 |
| Nakajima, S | 1 |
| Taira, T | 1 |
| Tokuyama, M | 1 |
| Kai, T | 1 |
| Okamoto, Y | 1 |
| Goya, S | 1 |
| Kashiwagi, Y | 1 |
| Grassi, L | 1 |
| Caraceni, A | 1 |
| Mitchell, AJ | 1 |
| Nanni, MG | 1 |
| Berardi, MA | 1 |
| Caruso, R | 1 |
| Riba, M | 1 |
| Stocker, L | 1 |
| Jellestad, L | 1 |
| Kram, BL | 1 |
| Kram, SJ | 1 |
| Brooks, KR | 1 |
| Serafim, RB | 1 |
| Bozza, FA | 1 |
| Soares, M | 1 |
| do Brasil, PE | 1 |
| Tura, BR | 1 |
| Ely, EW | 1 |
| Salluh, JI | 1 |
| Forcen, FE | 1 |
| Matsoukas, K | 1 |
| Alici, Y | 1 |
| Okumura, Y | 1 |
| Hatta, K | 1 |
| Wada, K | 1 |
| Takeuchi, T | 1 |
| Kishi, Y | 2 |
| Brahmbhatt, K | 1 |
| Whitgob, E | 1 |
| Brown, GD | 1 |
| Muzyk, AJ | 1 |
| Preud'homme, XA | 1 |
| Lawlor, PG | 1 |
| Quinn, S | 1 |
| Rowett, D | 1 |
| Sanderson, C | 1 |
| Hardy, J | 1 |
| Le, B | 1 |
| Eckermann, S | 1 |
| McCaffrey, N | 1 |
| Devilee, L | 1 |
| Fazekas, B | 1 |
| Hill, M | 1 |
| Currow, DC | 1 |
| Hsu, CW | 1 |
| Lee, Y | 1 |
| Lee, CY | 1 |
| Lin, PY | 1 |
| Edwards, LE | 1 |
| Hutchison, LB | 1 |
| Hornik, CD | 1 |
| Smith, PB | 1 |
| Cotten, CM | 1 |
| Bidegain, M | 1 |
| Gagnon, PR | 1 |
| Rahn, A | 1 |
| Briskman, I | 1 |
| Dubinski, R | 1 |
| Barak, Y | 1 |
| Andoh, H | 1 |
| Kato, K | 1 |
| Sato, R | 1 |
| Akama, F | 1 |
| Sakaguchi, T | 1 |
| Matsumoto, H | 1 |
| Alphs, L | 1 |
| Gopal, S | 1 |
| Karcher, K | 1 |
| Kent, J | 1 |
| Sliwa, JK | 1 |
| Kushner, S | 1 |
| Nuamah, I | 1 |
| Singh, J | 1 |
| Danivas, V | 1 |
| Behere, RV | 1 |
| Varambally, S | 1 |
| Rao, NP | 1 |
| Venkatasubramanian, G | 1 |
| Gangadhar, BN | 1 |
| Grover, S | 1 |
| Kumar, V | 1 |
| Chakrabarti, S | 1 |
| Tahir, TA | 1 |
| Farewell, D | 1 |
| Bisson, J | 1 |
| Jacobson, J | 1 |
| Munzig, E | 1 |
| Saager, L | 1 |
| Sessler, DI | 1 |
| Hakim, SM | 1 |
| Othman, AI | 1 |
| Naoum, DO | 1 |
| Kato, M | 1 |
| Okuyama, T | 1 |
| Thurber, S | 1 |
| Raiten, JM | 1 |
| Gutsche, JT | 1 |
| Freudenreich, O | 1 |
| Goff, DC | 1 |
| Morikawa, M | 1 |
| Kishimoto, T | 1 |
| Temple, MJ | 1 |
| Serio, RN | 1 |
| Parellada, E | 1 |
| Baeza, I | 1 |
| de Pablo, J | 1 |
| Martínez, G | 1 |
| Liu, CY | 1 |
| Juang, YY | 1 |
| Liang, HY | 1 |
| Lin, NC | 1 |
| Yeh, EK | 1 |
| Mittal, D | 1 |
| Jimerson, NA | 1 |
| Neely, EP | 1 |
| Johnson, WD | 1 |
| Kennedy, RE | 1 |
| Torres, RA | 1 |
| Nasrallah, HA | 1 |
| Gupta, N | 1 |
| Sharma, P | 1 |
| Mattoo, SK | 1 |
| Kim, JY | 1 |
| Jung, IK | 1 |
| Cho, SH | 1 |
| Kim, L | 1 |
| Kim, SH | 1 |
| Lee, BH | 1 |
| Lee, HJ | 1 |
| Kim, YK | 1 |
| Toda, H | 1 |
| Kusumi, I | 1 |
| Sasaki, Y | 1 |
| Ito, K | 1 |
| Koyama, T | 1 |
| Scharko, AM | 1 |
| Baker, EH | 1 |
| Kothari, P | 1 |
| Khattak, H | 1 |
| Lancaster, D | 1 |
| Halil, M | 1 |
| Cankurtaran, ES | 1 |
| Ozkayar, N | 1 |
| Cankurtaran, M | 1 |
| Ulger, Z | 1 |
| Yavuz, BB | 1 |
| Shorbagi, A | 1 |
| Ariogul, S | 1 |
| Kapetanovic, S | 1 |
| Simpson, GM | 1 |
| Ito, H | 1 |
| Harada, D | 1 |
| Hayashida, K | 1 |
| Ishino, H | 1 |
| Nakayama, K | 1 |
| Lonergan, E | 1 |
| Britton, AM | 1 |
| Luxenberg, J | 1 |
| Wyller, T | 1 |
| Miyaji, S | 1 |
| Yamamoto, K | 1 |
| Hoshino, S | 1 |
| Yamamoto, H | 1 |
| Sakai, Y | 1 |
| Miyaoka, H | 1 |
| Prakanrattana, U | 1 |
| Prapaitrakool, S | 1 |
| Ozbolt, LB | 1 |
| Paniagua, MA | 1 |
| Kaiser, RM | 1 |
| Chen, B | 1 |
| Cardasis, W | 1 |
| Sipahimalani, A | 1 |
| Masand, PS | 1 |
| Zarate, CA | 1 |
| Baldessarini, RJ | 1 |
| Siegel, AJ | 1 |
| Nakamura, A | 1 |
| McDonald, J | 1 |
| Muir-Hutchinson, LA | 1 |
| Cherkerzian, T | 1 |
| Tohen, M | 1 |
| Zayas, EM | 1 |
| Grossberg, GT | 1 |
| Tavcar, R | 1 |
| Dernovsek, MZ | 1 |
| Ravona-Springer, R | 1 |
| Dolberg, OT | 1 |
| Hirschmann, S | 1 |
| Grunhaus, L | 1 |
| Frank, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer[NCT01539733] | 101 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| Virtual Reality Stimulation to Relax and Reduce the Incidence of Delirium[NCT04498585] | 920 participants (Anticipated) | Interventional | 2021-04-14 | Suspended (stopped due to Decreased resources due to COVID-19) | |||
| HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial[NCT04833023] | Phase 3 | 72 participants (Anticipated) | Interventional | 2022-05-18 | Recruiting | ||
| Prospective, Double-Blind, Randomized Controlled Trial of Quetiapine as a Treatment for Delirium in Critically Ill Children[NCT03572257] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2019-04-15 | Withdrawn (stopped due to Closed due to inability to enroll) | ||
| Risperidone and Zotepine in the Treatment of Delirium[NCT00622011] | Phase 4 | 5 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to inadequate participant) | ||
| Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)[NCT01700816] | 40 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Low incidence of delirium.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | volume percentage (vol%) of red blood ce (Median) |
|---|---|
| Bright Light Therapy | 28.20 |
| Sham Light | 26.70 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | g/dl (Median) |
|---|---|
| Bright Light Therapy | 9.70 |
| Sham Light | 9.55 |
(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | days (Median) |
|---|---|
| Bright Light Therapy | 18 |
| Sham Light | 18.5 |
Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant
| Intervention | Participants (Count of Participants) |
|---|---|
| Bright Light Therapy | 1 |
| Sham Light | 0 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | thousand cells/uL (Median) |
|---|---|
| Bright Light Therapy | 39 |
| Sham Light | 33.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | M/uL (Median) |
|---|---|
| Bright Light Therapy | 3.21 |
| Sham Light | 2.93 |
"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant
| Intervention | units on a scale (Number) |
|---|---|
| Bright Light Therapy | 18 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | K/uL (Median) |
|---|---|
| Bright Light Therapy | 2.30 |
| Sham Light | 4.75 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mg/dl (Median) | |
|---|---|---|
| Serum Creatinine | Blood Urea Nitrogen (BUN) | |
| Bright Light Therapy | 0.66 | 9 |
| Sham Light | 0.75 | 8.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
| Intervention | mmol/L (Median) | |||
|---|---|---|---|---|
| Sodium (Na) | Potassium (K) | Chloride (Cl) | Carbon Dioxide (CO2) | |
| Bright Light Therapy | 139 | 3.6 | 105 | 24.9 |
| Sham Light | 138.0 | 3.80 | 103.0 | 25.10 |
21 reviews available for risperidone and Delirium
| Article | Year |
|---|---|
Delirium in the Neonate.
Topics: Antipsychotic Agents; Benzodiazepines; Child; Delirium; Humans; Infant; Infant, Newborn; Olanzapine; | 2022 |
Comparative efficacy and acceptability of pharmacological interventions for the treatment and prevention of delirium: A systematic review and network meta-analysis.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Network Meta-Analysis; Risperidone | 2020 |
Delirium in hospitalized patients: Risks and benefits of antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Haloperidol; Hospitalization; Humans; | 2017 |
Antipsychotics for treatment of delirium in hospitalised non-ICU patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Hospitalization; Humans | 2018 |
What do we really know about the treatment of delirium with antipsychotics? Ten key issues for delirium pharmacotherapy.
Topics: Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Haloperidol; Humans; Risperidone | 2013 |
Atypical antipsychotics in the treatment of delirium.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Humans; Olanzapine | 2013 |
The pharmacologic management of delirium in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Delirium; Dexmedetomidine; Dibenzothiazepi | 2014 |
[Sparse evidence of antipsychotic drugs for the treatment of delirium].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Delirium; Evidence-Based Medicine; Humans; Olanz | 2014 |
[Sparse evidence of antipsychotic drugs for the treatment of delirium].
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Delirium; Evidence-Based Medicine; Humans; Olanz | 2014 |
Management of delirium in palliative care: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholinesterase Inhibitors; Delirium; Disease Ma | 2015 |
Pharmacologic prevention and treatment of delirium in intensive care patients: A systematic review.
Topics: Antipsychotic Agents; Critical Care; Critical Illness; Delirium; Dexmedetomidine; Haloperidol; Human | 2015 |
Antipsychotic-induced akathisia in delirium: A systematic review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Delirium; Haloperidol; Humans; Prevalence; Risperidon | 2016 |
Diagnosis and Management of Delirium in Critically Ill Infants: Case Report and Review.
Topics: Abnormalities, Multiple; Antipsychotic Agents; Critical Illness; Delirium; Humans; Infant; Long QT S | 2016 |
Neurotoxicity and nephrotoxicity caused by combined use of lithium and risperidone: a case report and literature review.
Topics: Acute Kidney Injury; Antipsychotic Agents; Delirium; Drug Therapy, Combination; Humans; Lithium; Mal | 2016 |
Treatment of delirium in supportive and palliative care.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dopamine Antagonists; Haloperidol; Humans; Olanzapi | 2008 |
[Delirium--management in the hospital: diagnosis and treatment].
Topics: Aged; Antipsychotic Agents; Confusion; Delirium; Frail Elderly; Haloperidol; Hospitalization; Humans | 2008 |
Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Delirium; Drug Therapy, Combination; Evid | 2002 |
Atypical antipsychotics in the management of delirium: a review of the empirical literature.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Humans; Olanzapine; Piperazines | 2005 |
Atypical antipsychotics in the management of delirium: a review of the empirical literature.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Humans; Olanzapine; Piperazines | 2005 |
Atypical antipsychotics in the management of delirium: a review of the empirical literature.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Humans; Olanzapine; Piperazines | 2005 |
Atypical antipsychotics in the management of delirium: a review of the empirical literature.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Humans; Olanzapine; Piperazines | 2005 |
Antipsychotics for delirium.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Olanzapin | 2007 |
Atypical antipsychotics for the treatment of delirious elders.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Delirium; | 2008 |
The treatment of psychosis in late life.
Topics: Age Factors; Aged; Antipsychotic Agents; Clozapine; Decision Trees; Delirium; Diagnosis, Differentia | 1998 |
12 trials available for risperidone and Delirium
| Article | Year |
|---|---|
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine; | 2020 |
Antipsychotics Worsen Symptoms in Patients with Delirium Who Receive Palliative Care.
Topics: Administration, Oral; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Humans; Male; Pal | 2017 |
Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms of Delirium Among Patients in Palliative Care: A Randomized Clinical Trial.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Australia; Delirium; Double-Blind Method; Female; | 2017 |
Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Drug Administration Schedule; Female; | 2011 |
Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: a randomized trial.
Topics: Aged; Anesthesia, General; Antipsychotic Agents; Basal Ganglia Diseases; Cardiopulmonary Bypass; Cri | 2012 |
Treatment of delirium with risperidone in cancer patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Hallucinations; Humans; Male; Middl | 2012 |
Risperidone in the treatment of patients with delirium.
Topics: Aged; Antipsychotic Agents; Cognition Disorders; Delirium; Female; Health Status; Humans; Male; Midd | 2004 |
Risperidone in the treatment of delirium: results from a prospective open-label trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delirium; Drug Administration Schedule; Female; Healt | 2004 |
Effectiveness of risperidone in delirium.
Topics: Adult; Aged; Antipsychotic Agents; Delirium; Female; Humans; Male; Middle Aged; Risperidone | 2005 |
Antipsychotics and dopamine transporter gene polymorphisms in delirium patients.
Topics: Adult; Antipsychotic Agents; Delirium; Dopamine Plasma Membrane Transport Proteins; Female; Haloperi | 2005 |
Relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Delirium; Female; Humans; Male; Middle Aged; Prosp | 2005 |
Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery.
Topics: Antipsychotic Agents; Coronary Artery Bypass; Delirium; Epidemiologic Methods; Female; Humans; Male; | 2007 |
51 other studies available for risperidone and Delirium
| Article | Year |
|---|---|
Safety and Effectiveness of Perospirone in Comparison to Risperidone for Treatment of Delirium in Patients with Advanced Cancer: A Multicenter Prospective Observational Study in Real-World Psycho-Oncology Settings.
Topics: Aged; Antipsychotic Agents; Delirium; Humans; Isoindoles; Neoplasms; Psycho-Oncology; Risperidone; T | 2022 |
Prospective clinical intervention study of aripiprazole and risperidone in the management of postoperative delirium in elderly patients after cardiovascular surgery.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Delirium; Humans; Prospective Studies; Risperidone; Treatm | 2022 |
Post-discharge use of antipsychotics in patients with hospital-acquired delirium and associated risk of mortality - A population-based nested case-control study.
Topics: Aftercare; Antipsychotic Agents; Case-Control Studies; Delirium; Hospitals; Humans; Patient Discharg | 2023 |
The Efficacy of Low-Dose Risperidone Treatment for Post-Surgical Delirium in Elderly Orthopedic Patients.
Topics: Aged; Aged, 80 and over; Delirium; Female; Humans; Male; Orthopedics; Postoperative Complications; P | 2023 |
Old Habits Die Hard: Antipsychotics for Treatment of Delirium.
Topics: Adult; Antipsychotic Agents; Delirium; Habits; Humans; Risperidone | 2019 |
Topics: Child; Delirium; Electroencephalography; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; | 2020 |
Delirium in the NICU: Risk or Reality?
Topics: Adult; Antipsychotic Agents; Child; Delirium; Haloperidol; Humans; Infant, Newborn; Intensive Care U | 2021 |
In patients receiving palliative care, risperidone or haloperidol increased delirium symptoms vs placebo.
Topics: Antipsychotic Agents; Delirium; Double-Blind Method; Haloperidol; Humans; Palliative Care; Risperido | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research Is Needed.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
Neuroleptics for Delirium: More Research is Needed-Reply.
Topics: Antipsychotic Agents; Delirium; Haloperidol; Humans; Palliative Care; Risperidone | 2017 |
A case of autoimmune autonomic ganglionopathy with prolonged delirium.
Topics: Adrenergic alpha-Antagonists; Aged; Antipsychotic Agents; Autoimmune Diseases; Autonomic Nervous Sys | 2019 |
Association of the Clinical Subtype and Etiology for Delirium with the Outcome after Risperidone Monotherapy in Patients Having Cancer.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Checklist; Delirium; Female; Humans; Male; Middle Age | 2016 |
Successfully treated delirium in an extremely elderly patient by switching from risperidone to ramelteon.
Topics: Aged, 80 and over; Antipsychotic Agents; Delirium; Humans; Indenes; Male; Receptors, Melatonin; Risp | 2013 |
The diagnosis and management of delirium in infancy.
Topics: Antipsychotic Agents; Benzodiazepines; Child, Preschool; Delirium; Female; Humans; Infant; Male; Ola | 2013 |
Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Dibenzothiazepines; Female; Haloperidol; Huma | 2013 |
Delirium caused by a drug-drug interaction between bupropion and risperidone.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Bupropion; Citalop | 2014 |
Risperidone-induced neutropenia: an adverse side-effect in the palliative management of delirium in a patient with lymphoma.
Topics: Aged, 80 and over; Antipsychotic Agents; Delirium; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Ne | 2013 |
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Delirium; Dementia; Female; Haloperidol; | 2015 |
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; F | 2016 |
Challenges in the management of delirium: a case of augmentation with donepezil following inadequate response and adverse effects with risperidone.
Topics: Anticholinergic Syndrome; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Burns; Cholinestera | 2015 |
Implications of atypical antipsychotic prescribing in the intensive care unit.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Benzo | 2015 |
Expert opinions on the first-line pharmacological treatment for delirium in Japan: a conjoint analysis.
Topics: Aged; Antipsychotic Agents; Cross-Sectional Studies; Delirium; Expert Testimony; Female; Humans; Jap | 2016 |
Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine.
Topics: Catatonia; Delirium; Excitatory Amino Acid Antagonists; Humans; Liver Transplantation; Male; Memanti | 2016 |
A case of infant delirium in the neonatal intensive care unit.
Topics: Amines; Analgesics, Opioid; Anti-Anxiety Agents; Cardiac Catheterization; Cyclohexanecarboxylic Acid | 2017 |
Treating delirium in a general hospital: a descriptive study of prescribing patterns and outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Drug Prescriptions; Female; Hospital | 2010 |
Case of delirium complicated with pneumonia that improved with blonanserin administration.
Topics: Aged; Antipsychotic Agents; Delirium; Humans; Male; Piperazines; Piperidines; Pneumonia; Psychiatric | 2010 |
Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases.
Topics: Chemistry, Pharmaceutical; Clinical Trials as Topic; Conscious Sedation; Databases, Factual; Delayed | 2011 |
Electroconvulsive therapy in the treatment of delirious mania: a report of 2 patients.
Topics: Adolescent; Antimanic Agents; Bipolar Disorder; Catatonia; Delirium; Electroconvulsive Therapy; Fema | 2010 |
Randomised control trials for delirium: current evidence and statistical methods.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Female; Haloperidol; Humans; Male; Risperidone | 2012 |
Atypical antipsychotic medications to control symptoms of delirium in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Child, Preschool; Delirium; Dibenzothiazep | 2012 |
Targeted prophylaxis of postoperative delirium.
Topics: Antipsychotic Agents; Cardiopulmonary Bypass; Delirium; Female; Humans; Male; Postoperative Complica | 2012 |
Use of risperidone in cardiac surgery patients with subsyndromal delirium.
Topics: Antipsychotic Agents; Cardiopulmonary Bypass; Delirium; Female; Humans; Male; Postoperative Complica | 2012 |
Probable dementia with Lewy bodies and risperidone-induced delirium.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Humans; Lewy Body Disease; Male; Psychotic | 2002 |
Use of atypical anti-psychotics in the management of post-traumatic confusional states in traumatic brain injury.
Topics: Antipsychotic Agents; Brain Injuries; Delirium; Hallucinations; Humans; Male; Middle Aged; Risperido | 2003 |
Acute delirium associated with combined diphenhydramine and linezolid use.
Topics: Acetamides; Acute Disease; Delirium; Diphenhydramine; Drug Combinations; Drug Interactions; Duty to | 2004 |
Efficacy of risperidone in treating the hyperactive symptoms of delirium.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Fe | 2004 |
Case study: delirium in an adolescent girl with human immunodeficiency virus-associated dementia.
Topics: Adolescent; AIDS Dementia Complex; Antipsychotic Agents; Brain; Citalopram; Delirium; Drug Therapy, | 2006 |
Elderly patient with delirium after myocardial infarction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delirium; Humans; Hypotension; Male; Myocardial Infarct | 2006 |
Delirium in HIV-associated dementia.
Topics: Adolescent; AIDS Dementia Complex; Antipsychotic Agents; Brain; Citalopram; Cytochrome P-450 CYP2D6 | 2006 |
Injectable sustained-release risperidone: recurrence of delirium and treatment failure.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Delirium; France; Hallucinations; Humans; Injecti | 2006 |
[Psychiatry and sleep disorders--delirium].
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; I | 2006 |
Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Injections, | 2007 |
Delirium induced by lithium and risperidone combination.
Topics: Aged; Bipolar Disorder; Delirium; Drug Therapy, Combination; Female; Humans; Lithium; Risperidone | 1996 |
Use of risperidone in delirium: case reports.
Topics: Adolescent; Antipsychotic Agents; Basal Ganglia Diseases; Delirium; Humans; Male; Middle Aged; Rispe | 1997 |
Risperidone in the elderly: a pharmacoepidemiologic study.
Topics: Age Factors; Aged; Aged, 80 and over; Basal Ganglia Diseases; Cardiovascular Diseases; Comorbidity; | 1997 |
Risperidone-induced delirium.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Humans; Risperidone; Schizophrenia | 1998 |
Delirium in elderly patients treated with risperidone: a report of three cases.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Humans; Male; Risperidone | 1998 |
Delirium, consent to treatment, and Shakespeare. A geriatric experience.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition; Delirium; Female; Geriatric Psychiatry; Hu | 1999 |